Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Using 99mTc-ADAPT6 and 99mTc-DARPinG3 in HER2-positive Breast Cancer Patients Before System (Chemo/Targeted) Therapy.

NCT05376644 is registered in ClinicalTrials.gov with Tomsk National Research Medical Center of the Russian Academy of Sciences as lead sponsor.

NCT NCT05376644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05376644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Using 99mTc-ADAPT6 and 99mTc-DARPinG3 in HER2-positive Breast Cancer Patients Before System (Chemo/Targeted) Therapy.
Lead sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase
Not applicable
Overall status
Completed
Start date
May 1, 2022
Completion date
January 21, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female